16-member Tylonolide Derivatives for Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of antibiotic-resistant bacteria strains, such as MRSA and NDM-1 superbugs, poses a significant challenge in treating bacterial infections, as existing antibiotics lose effectiveness due to mechanisms like reduced permeability, efflux mechanisms, methylation of ribosome binding sites, and enzymatic inactivation, necessitating the development of new antibiotics with improved antibacterial profiles and reduced resistance.
Innovation Solution
Development of novel 20-, 23-modified 16-membered tylonolide antibiotic compounds represented by general Formula I or II, or their pharmaceutically acceptable salts, which involve structural modifications including optionally substituted alkyl, cycloalkyl, aryl, and heterocyclic groups, and specific reaction steps like reductive amination and activation with iodine, triphenylphosphine, and pyridine, to enhance binding affinity and reduce resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat bacterial infections, then initial antibacterial effectiveness is achieved, but antibiotic-resistant bacteria strains emerge over time rendering the drugs ineffective
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of macrolide antibiotics through systematic substitution at multiple positions (2, 6, 7, 9, 15, 16) with various functional groups including amino, hydroxyl, alkyl, and heterocyclic groups. These structural parameter changes create novel derivatives that maintain binding affinity to the 50S ribosomal subunit while evading bacterial resistance mechanisms such as efflux pumps and enzymatic inactivation, thereby restoring and extending long-term antibacterial effectiveness
Solution Approach 2:
The patent employs composite material principles by combining multiple functional groups and structural motifs within single antibiotic molecules. The compounds integrate macrolide core structures with diverse substituents (piperidinyl, pyrrolidinyl, oxazolyl, thiazolyl groups, aminoalkyl chains, hydroxyl groups) to create composite molecular architectures that simultaneously achieve enhanced binding affinity, improved pharmacokinetic properties, and resistance to multiple bacterial resistance mechanisms
2Reliability
If structural modifications are made to improve antibacterial activity, then binding affinity to ribosome increases, but molecular complexity increases
Solution Approach 1:
The patent applies local quality principles by introducing specific functional groups at strategically selected positions around the macrolide core structure. Each substitution (at positions 2, 6, 7, 9, 15, or 16) is designed to enhance local interactions with specific amino acid residues in the ribosomal binding site, thereby improving overall binding affinity through localized optimizations rather than random complexity increases
Solution Approach 2:
The patent segments the molecular modification approach by treating each substitutable position (2, 6, 7, 9, 15, 16) as an independent variable that can be optimized separately. This segmentation allows systematic exploration of structure-activity relationships at each position while maintaining the intact macrolide core, enabling controlled increase in complexity only where it contributes to binding affinity and antibacterial activity
3Adaptability or versatility
If new antibiotic compounds are developed to overcome resistance, then antibacterial spectrum expands, but development time and cost increase
Solution Approach 1:
The patent applies universality principles by designing a series of macrolide derivatives that maintain a common core structure and mechanism of action (binding to 50S ribosomal subunit) while varying substituents to target different bacterial species and resistance profiles. This multi-functional approach allows a single compound series to address Gram-positive bacteria, Gram-negative bacteria, and Mycoplasma species, expanding antibacterial spectrum without requiring entirely new development programs for each pathogen type
Solution Approach 2:
The patent employs preliminary action by pre-establishing a comprehensive substitution pattern framework that identifies all viable positions (2, 6, 7, 9, 15, 16) and acceptable functional groups for modification before actual compound synthesis. This preliminary structural planning, combined with structure-activity relationship guidance, enables more efficient synthesis and screening of candidate compounds, reducing development time compared to trial-and-error approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds demonstrate improved antibacterial activity against resistant pathogens, including Gram-positive and Gram-negative bacteria, and Mycoplasma species, with enhanced pharmacokinetic properties and reduced side effects, effectively addressing the issue of antibiotic resistance.
Implementation Method 1
The compounds of formula I and formula II can be prepared by a process which comprises the following steps: (1) reductive amination of a compound of formula III or formula IV with an amine of formula R1R2CHNH2
Implementation Method 2
(2) activation of an intermediate of formula V or formula VI with iodine, triphenylphosphine, and pyridine to form an intermediate of formula VII or formula VIII;
Data Source
AI summary
The invention discloses 20,23-modified novel derivatives of 16-membered demycarosyltylonolide antibiotics, which are useful against bacterial and mycoplasmic pathogens in humans and animals. Also claimed are pharmaceutical compositions of such derivatives and their use in treating bacterial and mycoplasmic infections in humans and animals.